Compare Abeona Therapeutics Inc (ABEO) vs EHang Holdings Ltd - ADR (EH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs EHang Holdings Ltd - ADR — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while EHang Holdings Ltd - ADR trades at $5.42 (market cap $417.53M). The key difference: Abeona Therapeutics Inc and EHang Holdings Ltd - ADR are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| ABEO | EH | |
|---|---|---|
Market Cap | $373.32M | $417.53M |
Sector | Health | Industrials |
52-Week High | $7.23 | $19.99 |
52-Week Low | $4.17 | $5.52 |
Enterprise Value | $228.22M | $357.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EHang Holdings trades at $5.52, down 12.52% over 24 hours, reflecting bearish technical signals and weak quarterly earnings. The company reported a net loss of $275.98 million for 2025 with a -77.56% net margin, though revenue reached $417.98 million. Recent news highlights volatility, including an 18% surge on June 15, 2026, following a Q1 2026 earnings miss reported by The Motley Fool on June 9, 2026.
The outlook remains challenged by persistent losses and high cash burn, but analyst consensus suggests moderate upside with a $7.75 price target. Key risks include execution delays in eVTOL commercialization and reliance on financing amid negative cash flows, while institutional sentiment is mixed with 40% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →
